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Smad-interacting protein-1 (Sip1) [Zinc finger homeobox (Zfhx1b)]
is a transcription factor implicated in the genesis of Mowat–Wilson
syndrome in humans. Sip1 expression in the dorsal telencephalon
of mouse embryos was documented from E12.5. We inactivated
the gene specifically in cortical precursors. This resulted in the lack
of the entire hippocampal formation. Sip1 mutant mice exhibited
death of differentiating cells and decreased proliferation in the
region of the prospective hippocampus and dentate gyrus. The
expression of the Wnt antagonist Sfrp1 was ectopically activated,
whereas the activity of the noncanonical Wnt effector, JNK, was
down-regulated in the embryonic hippocampus of mutant mice. In
cortical cells, Sip1 protein was detected on the promoter of Sfrp1
gene and both genes showed a mutually exclusive pattern of
expression suggesting that Sfrp1 expression is negatively regu-
lated by Sip1. Sip1 is therefore essential to the development of the
hippocampus and dentate gyrus, and is able to modulate Wnt
signaling in these regions.
development  sfrp1  knockout  telencephalon  cortex
Smad-interacting protein-1 (Sip1) is a transcription factor thatinteracts with Smads, implicating it as a regulator of TGF/
BMP signaling (1), acting either as repressor or activator (2–4).
SIP1 has been implicated in the genesis of Mowat–Wilson syn-
drome in humans (5–8). The syndrome exhibits microcephaly,
agenesis of the corpus callosum, cerebral atrophy and poor hip-
pocampal formation, as well as other non-brain-related congenital
defects (6).
The molecular pathways leading to these brain related abnor-
malities have not yet been elucidated (9–11). Sip1-deficient mouse
embryos show multiple defects at embryonic day (E)8.5 and die at
E9.5 (12).
Here, we report on the generation of mice that lack Sip1
throughout the entire dorsal telencephalon.Mutantmice survive to
juvenile age but lack the entire hippocampus and corpus callosum
by this stage. These mice have marked deficiencies in the develop-
ment of the hippocampal formation similar to those reported in
mice deficient in components of the Wnt signaling pathway. We
found Sfrp1 gene, which encodes the Secreted Frizzled-Related
Protein 1, an extracellular inhibitor of Wnt factors (13), to be
up-regulated in the hippocampus of Sip1 mutant mice. This was
accompanied by a down-regulation of JNK activity in the hip-
pocampus of Sip1 mutants. Sip1 protein was also detected on the
promoter of Sfrp1 gene in cortical cells, and we demonstrate that
expression of the two geneswasmutually exclusive in the developing
cerebral cortex. Our data provide evidence for a functional link
between Sip1 and the control of Wnt/JNK signaling in vivo. In
addition, the Sip1 mutant mouse provides a model system to clarify
the brain-related abnormalities in Mowat–Wilson syndrome.
Results
Sip1mRNA Expression and Gene Ablation in the Dorsal Telencephalon.
In the developing mouse brain, Sip1 mRNA was predominantly
detected in the telencephalon, basal ganglia (BG), and thalamus
(Fig. 1). By the onset of corticogenesis (E12.5), the developing
telencephalon showed strong Sip1 in situ hybridization (ISH) signals
in the postmitotic area of the cortex, although less-intense signals
were also found in the proliferative compartment, the ventricular
zone (VZ) (Fig. 1 a and b). At later embryonic stages (E16.5 and
E18.5), the strongest ISH signals in the developing neocortex
and hippocampus were located in the intermediate zone (IZ) and
cortical plate (CP) (Fig. 1 c, e, g, and i).
To inactivate Sip1 function specifically in the cerebral cortex,
Sip1 mutants were generated by crossing the Sip1exo7flox (14) and
the Emx1IRESCre (15) mouse lines. The specificity of the Sip1exo7
deletion in cortical tissue was verified by both PCR and radioactive
ISH with a riboprobe specific for exon7 [Fig. 1 and supporting
information (SI) Fig. 7].
In the nonmutant littermates (Fig. 1 c and g), this exo7 probe
produced a signal identical to that of a full probe (data not shown)
used previously in ISH studies with this gene. Conversely, in E16.5
mutant brains (Fig. 1d) the exo7 signal was not detected in the
dorsal telencephalon but remained unchanged in theVZof BGand
in the thalamus. At later stages (E18.5), we detected some Sip1
signal scattered throughout the dorsal telencephalon with relatively
higher intensity in the hippocampus (Fig. 1i). Because Sip1 was not
targeted for deletion in the BG (where it is also expressed), the
remaining Sip1 expression in the cortex could be attributed either
to the migrating interneurons that invade the cortex tangentially
from BG or to locally born cells that escaped Cre recombination.
Sip1 Deletion Affects Hippocampal Development. Sip1 mutants were
born with the expected Mendelian frequency and usually reached
the juvenile stage (3–4 weeks old) Overall brain size was smaller in
the mutants, possibly because of a general growth retardation (Fig.
2 and SI Fig. 8). Analysis of Nissl-stained sections of adult Sip1
mutant brains showed a remarkable phenotype in which both the
hippocampus and corpus callosum were consistently missing (Fig.
2). The first morphological onset of the phenotype was detected at
E15.5 (SI Fig. 9 Left), when the developing mutant hippocampus
appeared smaller than in control mice. Perinatally, the corpus
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callosum was absent, and all hippocampal fields were reduced in
size (SI Fig. 9c Center). The presence of reduced CA1 and CA3
fields of the hippocampus was confirmed by ISH with the markers
SCIP (16) and KA1 (17), respectively. The dentate gyrus (DG) was
almost absent, although a very few cells dorsal to CA fields
expressed the molecular marker of the DG, Prox1 (18) (SI Fig. 9c
Right).
Sip1 Ablation Increases Cell Death and Impairs Neural Progenitor Cell
Proliferation in the Hippocampus and DG.We first asked whether the
absence of Sip1 would affect neuronal differentiation in the hip-
pocampal formation, and thereby its normal size, by promoting
premature differentiation. For this, we tested the presence of Hu
andTuj1 differentiationmarkers and nestin as amarker of neuronal
progenitors at E13.5 and E15.5. Tuj1, Hu, and nestin were all
normally present in the brain of Sip1 mutants (SI Fig. 10), which
argues against the hypothesis of Sip1 function in suppressing
premature differentiation of neuronal progenitors.
To assess whether Sip1 is required for the normal proliferation
of hippocampal progenitors, we monitored the incorporation of
BrdU into the nuclei of cycling cells at the morphological onset of
the mutant phenotype (E14.5 and E15.5), using a 1.5-hour BrdU
pulse. The number of BrdU cells was quantified in two regions of
the developing hippocampus: the prospective DG and the CA1-
CA3 border of the hippocampus (Fig. 3 a–g). In the VZ of
CA1-CA3 regions, the number of proliferating cells was 20%
lower in Sip1 mutants than in control littermates (Fig. 3g). More-
over, a substantial decrease of 75% in proliferation rate was
detected within the secondary proliferative population, the region
responsible for the generation of DG cells. In the neocortical VZ,
however, BrdU analysis revealed no significant difference in pro-
liferation at E15.5 between mutant and control littermates (Fig. 3
c, d, and g).
We also performed a TUNEL assay to investigate whether the
cells in the hippocampus had responded to Sip1 deficiency by
activating apoptotic cell death. Before the morphological onset of
the mutant phenotype at E15.5, we did not detect apoptotic cell
death in either mutant or in control brains (data not shown).
Starting from E16.5, however, we found an increase in the number
of TUNEL-positive cells in the mutant hippocampi (Fig. 3 h and i).
At this stage, cells undergoing apoptosis were located in the CP of
the developing hippocampus, a region composed mainly of post-
migratory neurons, but not in the hippocampal ventricular and IZs
or in the neocortex. Later, at postnatal day (P)0, the majority of
dying cells was detected in the IZ and ventral part of the CP of the
hippocampus (Fig. 3 j and k). Increased apoptosis was also found
at later postnatal stages, as revealed by the high number of
TUNEL cells in the remaining hippocampus of Sip1mutants (Fig.
4 l andm and data not shown). Quantification of TUNEL cells at
E16.5, P0, and P8 (Fig. 4n) revealed a progressive increase in
apoptotic cell death in the mutant hippocampus (3-, 4-, and 5-fold,
respectively) (Fig. 3n). Thus, decreased proliferation and increased
apoptotic cell deathmay account for the total loss of the hippocam-
pus and DG in juvenile Sip1 mutant mice.
Initial Patterning of Dorsal Telencephalon Is Not Affected in Sip1
Mutants. The cortical hem is a transient signaling center located
between the presumptive hippocampus and choroid plexus (19).
This center is a source of Wnt and BMP signaling and is essential
for the normal development of the hippocampus (20). To deter-
mine whether the cortical hem is compromised in Sip1 mutant
brains, we examined the expression of the hem-specific markers,
Wnt3a and Wnt5a and found that the mRNA expression of both
markers was not affected in Sip1 mutant embryos (SI Fig. 11 c–f).
Because Sip1 is known to interact with BMP-SMADs (1), we asked
whether Sip1 deletion in the dorsal telencephalon would affect the
expression ofMsx1, a recognized downstream target of BMP, in the
dorsal midline (21). We found that Msx1 expression is not com-
promised in Sip1mutants (SI Fig. 11 a and b). Although we cannot
completely rule out the possibility that some other aspects of BMP
signaling are affected in Sip1 mutants, we did not detect any signs
Fig. 2. Juvenile Sip1 mutants lack the hippocampus and corpus callosum.
Nissl-stained sections of 3-week-old control (a and c) and mutant (b and d) mice
at two different rostro-caudal levels show, rostrally, the normal position of the
corpus callosum between the two cerebral hemispheres and its absence in Sip1
mutants (asterisks in a and b). Caudally, the entire hippocampal CA1–CA3 fields
and DG are missing in mutant mice and replaced by an enlarged ventricle
(asterisks in c and d).
Fig. 1. Sip1 is expressed in the developing mouse brain and is specifically
deleted in the Sip1flox/flox/ Emx1IRESCre dorsal telencephalon. (a and b) Coronal
sections of an E12.5 WT brain hybridized with a Sip1-specific riboprobe (a) show
expression of Sip1 in the cortex, BG and thalamus. In the cortex, Sip1 expression
is stronger in the CP and IZ than in the VZ and SVZ. At E16.5 (c and e) and E18.5
(gandh) Sip1 transcripts continue to be expressed at a higher level in postmitotic
areas than in mitotically active areas of the cortex. In Sip1mutants (d, f, h, and j)
expression of WT Sip1 mRNA is abolished in the developing Ncx and Hip (open
arrowheads) but is maintained in other regions such as BG and thalamus (filled
arrowheads). Hip, hippocampus; Ncx, neocortex; Th, thalamus; SVZ, subventricu-
lar zone. (b) Bright field of a. (i and j) Bright fields of g and h.
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of abnormal BMP signaling, such as a characteristic malformation
of the choroid plexus, the most dorsal structure of the cortex (21)
We also addressed whether the cortico–hippocampal boundary
was affected in Sip1 mutant brains. ISH with several molecular
markers (Fzd8 and Satb2 are shown in SI Fig. 12; for Tcf3 and Id3,
data not shown) did not reveal any anteriorisation of hippocampal
fields or posteriorisation of the neocortex (SI Fig. 12 Right)
These data indicate that Sip1 is neither required for the forma-
tion of the cortical midline and hem, nor for the initial patterning
of the dorsal telencephalon, at least after the onset of Emx1
expression. This conclusion is consistent with Sip1 being expressed
in the dorsal VZ at a relatively low level (Figs. 1a and 5a).
The Negative Regulator ofWnt Signaling, Sfrp1, Is Up-Regulated in the
Mutant Hippocampus.A series of genetic manipulations have shown
that Wnt signaling plays a pivotal role in the development of the
hippocampus. For example, mice deficient inWnt3a show a loss of
the entire hippocampal formation and corpus callosum (20). Sim-
ilar defects appear in mice that have reduced function in down-
stream mediators of the canonical Wnt signaling pathway, ranging
from Lef1/Tcf transcription factors (22) and -catenin (23) to
frizzled-9 (24). In addition, deletion of the transcription factor
Emx2, a target gene of Wnt signaling in the cortex (25), leads to a
reduced hippocampus and almost complete absence of the DG.
Sip1 is known to act as a transcriptional repressor (1), and Sip1
deletion leads to gross morphological and cell proliferation defects
that are comparable with those found in mice defective in compo-
nents of theWnt pathway.Hence, we reasoned that Sip1 could exert
a negative regulation on certain inhibitors of Wnt signaling. Thus,
we evaluated the expression of Sfrp genes known to be expressed in
the dorsal telencepalon (26). The expression of Sfrp2 was not
altered (data not shown), but the expression of Sfrp1 was dramat-
ically up-regulated in the Sip1mutant. In the wild-type (WT) E14.5
dorsal telencephalon, Sfrp1 expression has a very distinct rostro-
caudal gradient (Fig. 4A); it is expressed at high levels in the
neocortex, but it is not expressed in the hippocampus. Its expression
at this stage is limited to the VZ and is not found in the CP. In the
Sip1 mutant mice, Sfrp1 is ectopically expressed in the VZ of the
hippocampus. At later stages, the Sfrp1 up-regulation in the dorsal
telencephalon of mutant mice becomes much more pronounced.
Specifically, at E16.5–E18.5, it is strongly up-regulated in virtually
all postmitotic cells (arrowheads Fig. 4A). The up-regulation of
Sfrp1 in the mutant is much stronger in postmitotic than in
proliferating cells of the hippocampal VZ. This finding correlates
with a higher level of Sip1 transcripts in postmitotic than in VZ cells
(Figs. 1a and 5 a and b).
Sip1 Protein Is Detected on the Sfrp1 Promoter in Vivo, and the Sip1
Expression Pattern Is Complementary to That of Sfrp1. The ectopic
activation of Sfrp1 in the Sip1 mutant hippocampus and neocortex
could be either a primary or a secondary event in the Sip1-mediated
pathway. We therefore investigated the possibility of Sfrp1 being a
transcriptional target of Sip1. To reveal a possible interaction
between Sip1 and the Sfrp1 promoter, we performed a chromatin
immunoprecipitation assay (ChIP), using an antibody generated in
our lab (see SIMethods for details). The specificity of Sip1 antibody
was demonstrated by bothWestern blot and immunohistochemistry
(IHC) analyses (SI Fig. 13). After chromatin precipitation, the
presence of a Sip1 protein/Sfrp1 DNA complex was further ana-
lyzed by semiquantative PCR with several pairs of primers com-
plementary to sites spanning 8 kb of Sfrp1 upstream region. ChIP
assay with two of these pairs demonstrated that Sip1 protein was
detected within the region 2.5 kb upstream of Sfrp1 transcription
start. On the other hand, Sip1 protein was not detected within the
distal most 5-kb region from exon1 (Fig. 5h).
In addition, we performed ISH with Sip1 and Sfrp1 probes on
adjacent sections to correlate their expression patterns during
cortical development. At E14.5, Sfrp1 was highly expressed in the
neocortical VZ with no expression in the IZ and CP. In contrast,
Sip1 expression was low in the VZ and high in the IZ/CP (Fig. 5).
At P2, Sfrp1maintained its high expression in the VZ/SVZ with an
additional domain of expression in the CP of the cingulate cortex.
Fig. 3. Decreased proliferation and increased apoptotic cell death take place in the mutant hippocampus. Cells that incorporated BrdU after a 1.5-h pulse
were detected on coronal sections of E14.5 (a and b) and E15.5 (c and d) brains. Note the reduced number of BrdU cells of the secondary proliferative
population (SPP) (arrowheads in a–d; e and f show high magnification of boxes in c and d) in the mutant brains (b and d) when compared with controls
(a and c). The number of proliferating BrdU cells at E15.5 (c and d) was quantified in the VZ of the developing hippocampus (small dashed box), neocortex
(vertical box), and in the SPP (large dashed box) of three independent pairs of mutant and control brains in a several corresponding sections (mutant, n
29; control, n  27). Results were normalized to the area and expressed in micrometers squared. Statistical analysis was performed by using Student’s t
test. ***, P  0.0001. Note the 20% and 75% decreases in cell proliferation in the SPP and VZ, respectively, of the mutant hippocampus (g). Apoptotic
cell death was greater at E16.5 in the CP of the developing hippocampus in the mutant (i) than in the control (h) brains. At P0, substantial apoptosis was
found in cells located in the ventral part of the hippocampal CP and IZ of the mutant brain (k) although a few scattered TUNEL cells could also be found
in control brains (j). At P10, many apoptotic cells were found in the gray matter (m) but none in the controls (l). The number of TUNEL cells at E15.5, P0,
and P8 (n) was quantified in the developing hippocampus of two independent pairs of mutant and control brains for each stage in corresponding sections
(mutant, n  15; control, n  17).








Sip1 expression in the late CP was also complementary to that of
Sfrp1 expression, being excluded from Sfrp1-positive territory (Fig.
5). Collectively, these data suggest that Sip1 is a direct negative
regulator of Sfrp1 expression.
Canonical Wnt Signaling Is Not Significantly Impaired in the Sip1
Mutant Hippocampal CA1–CA3 Fields. We investigated whether the
transcription of canonical Wnt downstream factors was affected in
Sip1mutants. At the stages analyzed, neither the expression ofWnt
mediator Lef1, nor of Emx2 and Axin2, known downstream target
genes of canonicalWnts (27), was affected (SI Fig. 12Right). At the
protein level, the hippocampus of Sip1 mutants and control litter-
mates showed a similar distribution of -catenin immunoreactivity
within the developing hippocampus (data not shown). The levels of
total and the activated fraction of -catenin appeared equivalent
between mutant and control samples, as shown by Western blot
analysis (Fig. 4B).
Activity of a Downstream Effecter of NoncanonicalWnt Signaling, JNK,
Is Inhibited in the Sip1 Mutant Medial Cortex During Embryonic
Development. Next, we asked whether Sfrp1 up-regulation in Sip1
mutants coincided with an impairment of noncanonical Wnt me-
diators. NoncanonicalWnt pathways are independent of -catenin.
At least two noncanonical Wnt pathways are known: one mediated
by JNK, the other dependent onCa2 (28). Themain effecter of the
latter, the Ca2-dependent calmodulin kinase II, starts to be
expressed postnatally in the murine brain. On the other hand, JNK
is expressed in the dorsal telencephalon IZ already from embryonic
stages (29), and JNK-mediated Wnt signaling has been shown to
modulate dendritic development in cultured hippocampal cells.
We therefore looked for possible changes in JNK activity, using
an antibody that specifically recognizes activated JNK1-3 (30). At
E15.5, the developing medial cortex of Sip1 mutants showed a
dramatic decrease in the levels of the activated form of JNK1-3
when compared with WT littermates (Fig. 4C). Neither the total
Fig. 5. SFRP1 is a target of SIP1 in the cerebral cortex. (a–f )Sfrp1andSip1mRNA
expression in the developing cortex. Sip1 (a) and Sfrp1 (b) expression at E14.5.
Filled arrowheads depict low but uniform expression of Sip1 in the VZ of neo-
cortex and hippocampus. Empty arrowheads depict regions with no Sip1 expres-
sion. (c–f ) Sip1 (a) and Sfrp1 (b) expression in the cerebral cortex at P2. Yellow
dashed lines demarcate the borders of Sfrp1 expression. (g) Putative Sip1 binding
sites and positions of amplicons for ChIP assay within the upstream genomic
region of Sfrp1. (h) Semiquantitative PCR analysis of four amplicons containing
putative Sip1 binding sites on SFRP1 promoter after ChIP (upper lane) and
amplification of input DNA (lower row). Sip1 was detected within the 2.5-kb
upstream region from the transcription initiation site (amplicons 1 and 2) but not
within the more distal region (amplicons 3 and 4). Samples with () and without
() added antibody against Sip1 are indicated.
Fig. 4. Wnt pathway is affected in SIP1 mutant hippocompus. (A) Secreted
frizzled-related protein 1 (Sfrp1) mRNA is up-regulated and ectopically expressed
in Sip1 mutants. Because E14.5 Sfrp1 transcripts in the dorsal telencephalon are
normally confined to the neocortical VZ but are excluded from the VZ of the
hippocampal anlage at the onset of hippocampal development (a). In Sip1
mutants, however, Sfrp1 is not only found in the neocortical VZ but is also
ectopically expressed in the hippocampal VZ (b). By E16.5 (c and d) and E18.5 (e
and f ), Sfrp1 is strongly up-regulated in the mutant in both the proliferating and
postmitotic areas of the cortex. In control brains at E16.5, Sfrp1 is not expressed
in postmitotic cells (arrowhead in c) but is up-regulated in postmitotic cells of the
mutant (arrowhead in d). At E18.5 (e), Sfrp1 starts to be expressed in some
postmitotic cells of the neocortex but not in the hippocampus. In the mutant
brains (f), however, Sfrp1 is up-regulated in all cortical regions. (Dashed lines
demarcate the normal medial border of Sfrp1 expression.) (B) The activation of
-catenin is not impaired in the Sip1mutant hippocampus. Western blot analysis
of E15.5 medial cortex total protein extract of two independent pairs of mutant
(Mut) and control (WT) brains was performed by using the pan -catenin anti-
body and an antibody recognizing only the active (nonphosporylated) form of
-catenin. In both cases, a 92-kDa band was detected with equal intensity in
mutants and controls. (C) The active (phosphorylated) form of JNK1-3 (45 kDa)
is down-regulated in the mutant E15.5 hippocampus, whereas the total level of
JNK1-3 is not changed. The amount of protein loaded was controlled with
anti-GAPDH and anti-TujI.
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levels of JNK1-3, nor those of the neuronal marker TujI differed
between mutant and control hippocampi (Fig. 4C).
We also asked whether lower JNK1-3 activity is maintained in
Sip1mutants at postnatal stages. To our surprise, we did not detect
any significant differences in JNK1-3 activity at P0 or P1 between
mutant and WT animals (data not shown). However, this might
reflect the differences in tissue composition of the medial cortex
between E15.5 and P0 mutant brains (see Discussion for details).
Discussion
Sip1 is expressed in the VZ of the developing dorsal telencephalon
at a low level, and at a high level in the postmitotic cells. Sip1
ablation in the dorsal telencephalon leads to a loss of the entire
hippocampal formation and corpus callosum in the adult. We
demonstrate that the loss of the hippocampus in Sip1mutant mice
is a result of progressive degeneration by apoptosis. SIP1 has been
implicated in the genesis of Mowat–Wilson syndrome in humans
(5–8). The syndrome also exhibits, with variable penetrance, mi-
crocephaly, agenesis of the corpus callosum, cerebral atrophy, and
poor hippocampal formation, as well as other non-brain-related
congenital defects (6). Interestingly, although in humans Mowat–
Wilson syndrome is caused by SIP1 heterozygousmutations, we did
not detect significant differences between heterozygous and WT
mice. Itmight indicate that either humans aremore sensitive to Sip1
dosage thanmice, or humanmutations produce dominant-negative
forms of Sip1 protein. Human patients exhibit microcephaly, as do
our mutant mice. However, in mice, microcephaly does not seem to
be an isolated condition but is possibly a result of general postnatal
growth retardation and dwarfism. The physiological basis of the
dwarfism in Sip1 mutants is not clear. It is unlikely to be caused by
Sip1 deletion in the cerebral cortex, because this brain region is not
involved in the control of general growth. Probably, it is triggered
by Emx1-Cre activity in another tissue where Sip1 plays an impor-
tant role. Sip1 juvenile mutant mice also show some degree of
lateral ventricle enlargement, but this is unlikely to cause hippocam-
pal degeneration, because even in severe cases of hydrocephalus in
rats, cell death in the hippocampus was not observed (31).
Because Sip1 is known to interactwithBMP-Smads, the expected
phenotype would reflect strong deficiencies in BMP signaling in the
dorsal telencephalon. However, Sip1 mutants show a normal cho-
roid plexus, and the expression of Msx1, one of the few well
characterized BMP targets, is not affected in the dorsal telence-
phalic midline, which suggest that BMP signaling is not severely
impaired. Previous studies have shown that Wnt signaling is re-
quired for normal hippocampal development (20, 22–24). Here, we
identify Sip1 as an agonist of theWnt pathway in the hippocampus.
It is noteworthy that morphological abnormalities in Sip1 mutant
brains are preceded by a strong up-regulation of Sfrp1, a known
extracellular antagonist of theWnt pathway. In the developingWT
telencephalon, Sfrp1 is expressed in theVZof the neocortex but not
in theVZ of the hippocampus. In the Sip1mutants, Sfrp1 is strongly
up-regulated at E14.5 in the VZ of hippocampus. On the other
hand, in theWTcerebral cortexSfrp1 is expressed only in areaswith
low Sip1 expression.We also detected Sip1 protein on the promoter
of Sfrp1 gene in cortical cells by ChIP assay. These findings suggest
that up-regulation of Sfrp1 in the hippocampus could be a molec-
ular cause of the observed hippocampal abnormalities in Sip1
mutant brains. It is not clear whether the Sfrp1 ectopic activation
is the sole cause of hippocampal degeneration in Sip1 mutants or
whether there are other direct targets of Sip1 that also contribute
to the phenotype. This needs to be addressed in detail in the future
by studying, for example, Sip1/Sfrp1 compound mutant mice.
Although the phenotype of the Sip1 mutant in the hippocampus
is reminiscent of theWnt3a or -catenin mutant phenotypes, there
are marked differences. In Wnt3a and -catenin mutants the
hippocampal formation is absent since early development, whereas
in Sip1mutants, reduced hippocampal fields are still present during
early development but disappear postnatally. Themain cause of the
underdeveloped hippocampus in theWnt3amutantwas reported to
be decreased proliferation, and no cell death was detected. In the
case of the Sip1 mutant, the proliferation rate is decreased, but
apoptosis largely contributes to the reduction of hippocampal size.
In contrast to Sip1 mutants, no massive cell death was detected in
Wnt3a or in -catenin conditional mutants (20, 22, 23), which can
be explained by stage-specific differences. The authors of refs. 20,
22, and 23 did not elaborate on their apoptosis analysis beyond
E14.5, the stage where we also detected no cell death. Another
possible explanation could be that noncanonical rather than ca-
nonical Wnt signaling is affected in Sip1 mutants.
It has been shown that the compound mutation of Jnk1 and Jnk2
is associatedwith increased apoptosis in the forebrain (32).A recent
report (24) suggests that noncanonical Wnt signaling can regulate
cell death in the hippocampal formation. Increased apoptosis
observed in the postmitotic regions of the developing hippocampus
from in Sip1 mutants is likely to be a consequence of the JNK
inactivation. In this scenario, Wnt signaling controls not only cell
proliferation of hippocampal cells but also cell survival by modu-
lation of JNK activity. Surprisingly, we did not detect differences in
JNK activity within the medial cortex in neonatal brains. It is
possible that in the postnatal brain, molecules other than JNK can
mediate apoptosis in the Sip1-deficient hippocampus.Alternatively,
it might reflect differences in the composition of tissue samples
extracted for theWestern analysis at different stages. Indeed, when
isolating tissue samples for Western analysis, we included hip-
pocampus, DG, subiculum and part of the cingulate cortex. At
E15.5, the relative proportions of these parts of the medial cortex
did not differ drastically between WT and mutants. In contrast, in
P2 mutant brains, a substantial part of hippocampus and DG had
already degenerated (SI Fig. 9Middle). In this case,most protein for
Fig. 6. Model of Sip1 function in the dorsal telencephalon. In the WT cortex,
cells expressing Sip1at a very high level (postmitotic cells) do not coexpress Sfrp1.
VZ cells of the neocortex, in contrast to VZ cells of the hippocampus, do coexpress
Sip1 and Sfrp1. It is likely that a high level of Sip1 expression alone is enough to
down-regulate Sfrp1 expression in postmitotic cells. Conversely, the low level of
expression of Sip1 in the neocortical VZ cells is not sufficient to suppress the
expression of Sfrp1. However, in VZ cells of the hippocampus, where Sip1 expres-
sion is similar to that in neocortical VZ cells, Sip1 and Sfrp1 are not coexpressed.
Thus, it is likely that Sip1 (when expressed at a low level) requires other cofactors,
such as BMP-Smads, to suppress Sfrp1. The hippocampus is situated closer to the
localized source of BMP signals than is the neocortex. Therefore, it is conceivable
that the level of activated BMP-Smads is higher in the hippocampus than in the
neocortex. On the other hand, Sip1 can interact with Smads, making them good
candidates to help Sip1 regulate Sfrp1 in cells with low Sip1 expression. In the
hippocampus,Sip1positively controls JNKactivitypossiblybynegative regulation
of Sfrp1 expression. In Sip1mutants, Sfrp1 may inhibit noncanonical Wnt signal-
ing in the hippocampus, because it is no longer subject to Sip1-mediated repres-
sion. This may result in inactivation of JNK, which, in turn, induces apoptotic cell
death.








the Western was extracted from subiculum and cingulate cortex,
two regions preserved in Sip1mutants. It is not clear whether Sfrp1
up-regulation is themain reason for JNK inactivation in themutant
hippocampus. However, given that Sfrp1 is a recognized inhibitor
of both canonical and noncanonical Wnt pathways, its overexpres-
sion in the Sip1mutant hippocampus is likely to contribute to JNK
inactivation (Fig. 6).
Collectively, our data demonstrate that Sip1 is indispensable for
the normal development and maintenance of the hippocampal
formation. The absence of Sip1 induces up-regulation of Sfrp1
expression in the developing hippocampus, inhibits JNK activity
and eventually results in decreased proliferation of neuronal pro-
genitors and in apoptosis of postmitotic cells. Our data suggest that
in the hippocampus, Sip1 functions as a positive regulator of
noncanonicalWnt signaling by regulating the expression of theWnt
inhibitor Sfrp1.
Methods
Mice. The animals were kept on a mixed CD1/C57B6 background.
Genotyping was performed as described in ref. 12. All animal
manipulationswere carried out in accordancewithGerman lawand
were approved by the Bezirksregierung Braunschweig. Pregnant
females were killed by cervical dislocation. Brains were fixed either
by immersion (embryonic and perinatal brains) into or perfused
(adult brains) by freshly prepared 4% paraformaldehyde-PBS
overnight at 4°C and then washed, dehydrated, and embedded in
wax according to standard protocols.
ISH, IHC, and Cell Death Assay. Radioactive ISH and emulsion
autoradiography were performed essentially as described in ref. 33
with the only modification that hybridization buffer contained 200
mg/ml of SPthio-ATP (Roche Diagnostics, Mannheim, Germany)
to block nonspecific binding of labeled RNA. Nonradioactive ISH
was performed as described in ref. 34. The following probes were
used: SCIP and Prox1; Emx2 (Ep1.3), Wnt3a, Wnt5a, Wnt8b;
Axin2; and Sfrp1 (RZPD, Berlin, Germany; entry no. 7305480).
IHC was performed according to standard protocols (See SI
Methods for details). All experiments were repeated at least 3 times
with tissue samples from independent litters.
The following antibodies were used: anti-BrdU (1:100; Roche
Diagnostics; catalog no. 1170376), anti-Nestin (1:100; Chemicon,
Temecula, CA; catalog no. MAB353), anti-TujI (1:300; Sigma–
Aldrich, Seelze, Germany; catalog no. T8660), anti--Cat (IHC
1:100; BD Biosciences, San Jose, CA; catalog no. 610153), goat
anti-mouse-HRP (1:5,000; Chemicon), and rabbit anti-mouse-Cy3
and goat anti-rabbit-Cy5 (Jackson ImmunoResearch, West Grove,
PA). Cell death was assessed by TUNEL assay on paraffin sections,
using the Apoptag fluorescein direct in situ apoptosis detection kit
(Chemicon).
Western Blot Analysis. Tissue from the medial telencephalon of
E15.5 embryoswas extracted and suspended inTritonX-100 buffer.
Western blot analysis was performed by using the ECL kit (Am-
ersham Pharmacia, Uppsala, Sweden) according to the manufac-
turer’s instructions. The antibodies usedwere anti-b-Cat (1:500; BD
Biosciences; catalog no. 610153), anti-Active b-Cat (1:250 Upstate
Biotechnology, Lake Placid, NY; catalog no. 05-665), anti-GAPDH
(1:500; Chemicon; catalog no. MAB374), and goat anti-mouse-
HRP (1:5,000; Chemicon).
Generation of Antibodies Against Sip1 Protein. To produce antibody
against Sip1 we generated a peptide based on predicted protein
sequence: CDPPLRLTKSSHFTNI (754–769 aa). Antibody was
produced in rabbit as described in ref. 35 and verified by Western
blot analysis and IHC (see SI Fig. 13 and SI Methods).
ChIP Assay.Mouse embryonic cortex (E17.5 or E 18.5) was used as
a tissue source of chromatin. ChIP and a semiquantitative PCR
assay were performed as described in SI Methods.
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